As Merck’s Keytruda Gains Momentum, Investors Look To The Future
This article was originally published in The Pink Sheet Daily
Executive Summary
Keytruda, already the first anti-PD-1 drug to market for melanoma, received FDA breakthrough therapy designation for an indication in lung cancer. The drug’s long-term potential – and upcoming data on a two-drug hepatitis C combo – helped to offset a decline in Merck’s third quarter sales.